Edesa Biotech appoints Peter Weiler as CFO effective May 1, 2025, replacing Stephen Lemieux

Edesa Biotech, Inc.

Stephen Lemieux resigns as CFO effective May 1, 2025, to pursue other opportunities; will continue as a senior financial advisor under a consulting agreement.
Peter J. Weiler appointed CFO effective May 1, 2025; base salary of $300,000 USD per annum, target annual bonus of 40% of base salary, and $2,000/month auto allowance.
Weiler previously served as President of Exzell Pharma, Inc., and held business development roles at Biosyent Inc. and Cipher Pharmaceuticals Inc.
If terminated without cause, Weiler receives 12-24 months base salary plus benefits; enhanced change-of-control severance of 24 months base salary.
Lemieux's departure not due to any disagreement with Edesa; transition is planned and orderly.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Peter J. Weiler

Chief Financial Officer

EDSA · Edesa Biotech, Inc.

Effective: 2025-05-01
Filed: April 4, 2025, 7:59 PM ET

the Company appointed Peter J. Weiler to serve as the Company’s Chief Financial Officer, effective May 1, 2025

Departed

Stephen Lemieux

Chief Financial Officer

EDSA · Edesa Biotech, Inc.

Effective: 2025-05-01
Successor: Peter J. Weiler
Filed: April 4, 2025, 7:59 PM ET

Stephen Lemieux, Chief Financial Officer of Edesa Biotech, Inc. (the “Company”), notified the Company of his intention to resign from his position and responsibilities as Chief Financial Officer, effective May 1, 2025, to pursue another professional opportunity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter J. Weiler was appointed as Chief Financial Officer at Edesa Biotech, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

the Company appointed Peter J. Weiler to serve as the Company’s Chief Financial Officer, effective May 1, 2025

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Lemieux resigned as Chief Financial Officer at Edesa Biotech, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

Stephen Lemieux, Chief Financial Officer of Edesa Biotech, Inc. (the “Company”), notified the Company of his intention to resign from his position and responsibilities as Chief Financial Officer, effective May 1, 2025, to pursue another professional opportunity.

View on SEC.gov

Edesa Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-25-002027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.